NEW YORK, April 15, 2026 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.
Read more at prnewswire.com